CGA
IDXX icon

Crescent Grove Advisors’s Idexx Laboratories IDXX Stock Holding History

Crescent Grove Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-321
Closed -$205K – 306
2025
Q3 		$205K Buy
+321
New +$195K 0.02% 281
2022
Q2 		– Sell
-637
Closed -$348K – 281
2022
Q1 		$348K Buy
637
+52
+9% +$27.4K 0.03% 210
2021
Q4 		$385K Hold
585
– – 0.04% 202
2021
Q3 		$364K Hold
585
– – 0.04% 183
2021
Q2 		$369K Buy
+585
New +$323K 0.04% 171

Other funds holding IDXX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Crescent Grove Advisors's IDXX Position: Q4 2025 in Review

Crescent Grove Advisors sold out of Idexx Laboratories (IDXX) in Q4 2025, closing a stake of 321 shares — an estimated $205K sold.

Crescent Grove Advisors first reported a position in IDXX in Q2 2021 and held it in 5 quarters. The position peaked at $385K in Q4 2021. 1,386 funds tracked by Wall St. Rank hold IDXX as of Q4 2025.

  • Crescent Grove Advisors reported no remaining Idexx Laboratories position as of Q4 2025 after selling out during the quarter.
  • Crescent Grove Advisors sold 321 Idexx Laboratories shares in Q4 2025, an estimated $205K.
  • Crescent Grove Advisors first reported a position in Idexx Laboratories in Q2 2021 and held it in 5 quarters.
  • Crescent Grove Advisors's Idexx Laboratories position peaked at $385K in Q4 2021.
  • 1,386 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2025.

Based on Crescent Grove Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.